🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to unveil this new Nvelop Therapeutics DLVR-M platform today at the ASGCT annual meeting #ASGCT2024! DLVR-M is based on foundational work done by Peter Cabeceiras (now at Nvelop) in my former @MGH_RI laboratory. See details in tweet below.

As #ASGCT2024 nears its end, I'm excited to attend Poster Session 3 this afternoon. I also look forward to answering questions and talking about the GUIDE-seq & ONE-seq assays originally developed in my lab @MGH_RI (details below). linkedin.com/posts/sequre-d…

Great fun & very exciting to finally unveil Nvelop Therapeutics's DLVR-M platform with co-inventor Peter Cabeceiras at #ASGCT2024 in Baltimore last week. DLVR-M is based on work originally done by Peter during his Ph.D. work in my lab at the @MGH_RI. linkedin.com/posts/nveloptx…

On a sunny day, you might find Ligi taking a break from her gene editing work to spend a minute on our balcony, feeling as nourished as the plants in her lovingly curated garden. She is a microbiologist by training with good lab hands to house her green thumb.

When Martha walked into Arena's first holiday party and saw chalk drawings of holly in the shape of DNA, she didn't see a decoration. She saw an invitation. We celebrate our doodlers, designers, musicians, and artists of all kinds. Creativity out of lab begets creativity in lab.

Polyglot Giulia Oliva speaks English, Greek, French, and her native Italian. She would love to learn more but is busy with another manner of translation—turning her splendido mind to generating insights in the lab that she hopes to translate to new ways of treating disease.

Like some modern-day reverse Christopher Wren, Tasos might have been an architect but brought his design sense to the molecular scale. Fueled by espresso, this physician-scientist-dad-of-a-toddler never loses sight of the potential impact of his role. He could use a nap though.

Ken Lam is as humble as they come, but don't be mistaken. During presentations, his kindly asked but searingly insightful questions have been known to leave jaws on the floor. Penetrating minds like his are invaluable to shortening the path from insights to therapeutics.

Delighted to share this news. Combining SeQureDx’s & Integrated DNA Technologies's innovative technologies will enhance precision and safety in gene editing, bringing transformative solutions to researchers and patients worldwide. #CRISPR #GeneEditing

Always good for a laugh, Dan Gray—voted most likely to reference the Peloponnesian War while talking science—hails from a literary family. Though he broke from tradition to study science, he reads voraciously, and his interests—like his thinking—run both broad and deep.

On Friday, October 25th, Nvelop will deliver an oral presentation at the 31st Annual ESGCT Congress. Showcasing the latest preclinical data on DLVR-M, this presentation will further demonstrate the programmability and in vivo validation of our novel delivery platform. Read

Dave is a dreamer and a doodler who won our first t-shirt design contest, but you won't find him at the back of the class. His laid-back vibe belies a mind bursting with ideas and insights that challenge, inspire, and fuel an infectious desire to turn them into hope for patients.

Very excited about the first preprint from our lab TU München! This is a fun gene & cell therapy collaboration led by Andrea Schmidts's Lab. We use generative #AI to design new #CARTcell therapies. Check out Andrea's thread & thanks to the whole team! biorxiv.org/content/10.110…

Very cool new work from the labs of Andrea Schmidts and Julian Grünewald using AI to rapidly engineer new binders for CAR-T cells: biorxiv.org/content/10.110… #GenerativeAI #CARTcell

It's been a year of growth for Arena, so we were delighted to strengthen bonds and forge new ones while flexing our arcade skills at the holiday party. As we look ahead to the next year, Arena's focus continues to be human-biology-first. Emphasis on human.

Arena co-founder Stuart Schreiber, together with Doug Melton and Michael Mina, talked to Harvard Magazine about recognizing an opportunity to transform medicine by overcoming inherent inefficiencies in the current ecosystem. harvardmagazine.com/2025/01/harvar…